<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00655525</url>
  </required_header>
  <id_info>
    <org_study_id>080191</org_study_id>
    <secondary_id>R21AT003844-01A2</secondary_id>
    <nct_id>NCT00655525</nct_id>
  </id_info>
  <brief_title>Omega-3 Fatty Acid Administration in Dialysis Patients</brief_title>
  <official_title>Omega-3 Fatty Acid Administration in Dialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of this study is to examine the role of fish oil supplementation in
      ameliorating the inflammatory state of uremia and the related muscle protein catabolism
      associated with this disease state. We hypothesize that if administered for a period of 3
      months, fish oil will improve the chronic uremic inflammation. We further hypothesize that
      fish oil administration will improve the muscle protein breakdown associated with uremia and
      inflammation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A decrease in pro-inflammatory cytokine production (TNF-alpha) by peripheral blood mononuclear cells (PBMC)</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>A decrease in muscle protein breakdown</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>A decrease in concentration of acute phase reactants (serum C-reactive protein and plasma pro-inflammatory cytokines)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>An increase in concentration of nutritional biomarkers (serum albumin and serum prealbumin)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>fish oil</intervention_name>
    <description>2.9 g of fish oil (2:1 EPA:DHA) administered orally every day for 3 months</description>
    <arm_group_label>1</arm_group_label>
    <other_name>eicosapentaenoic acid/docosahexaenoic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo administered orally every day for 3 months</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients on CHD for more than 6 months;

          -  Ability to read and sign the consent form;

          -  Have acceptable dialysis adequacy (Kt/V &gt; 1.2);

          -  Use biocompatible hemodialysis membrane;

          -  Have a patent, well functioning, arteriovenous dialysis access or permanent dialysis
             catheter (no other option for arteriovenous access);

          -  Signs of chronic inflammation (average CRP of â‰¥ 5 mg/L for 3 consecutive measurements)

        Exclusion Criteria:

          -  Pregnancy;

          -  Intolerance to the study medication;

          -  Severe, unstable, active, or chronic inflammatory disease (active infection, active
             connective tissue disorder, active cancer, HIV, liver disease);

          -  Diabetes mellitus on insulin therapy;

          -  Hospitalization within 1 month prior to the study;

          -  Malfunctioning arterial-venous vascular access (recirculation and/or blood flow &lt; 500
             ml/min);

          -  Patients receiving steroids (&gt; 5 mg/day) and/or other immunosuppressive agents;

          -  Life-expectancy less than 6 months;

          -  Age less than 18 years old;

          -  Atrial fibrillation (only for those undergoing the optional Pulse Wave Velocity);

          -  Hypersensitivity to organic nitrates, isosorbide, or nitroglycerin (only for those
             undergoing the optional brachial artery Doppler).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alp Ikizler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2008</study_first_submitted>
  <study_first_submitted_qc>April 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2008</study_first_posted>
  <last_update_submitted>April 22, 2014</last_update_submitted>
  <last_update_submitted_qc>April 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Alp Ikizler</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>inflammation</keyword>
  <keyword>end stage renal disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

